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TO THE EDITOR
Three rare autosomal-recessive inherited
diseases are associated with defective
nucleotide excision repair: xeroderma
pigmentosum (XP), Cockayne syndrome,
and trichothiodystrophy (Bootsma et al.,
2002). XP patients are sun-sensitive and
skin cancer prone. Their skin cancer risk
is approximately 1,000 times higher
compared to the normal population.
Cockayne syndrome and trichothiody-
strophy patients are not skin cancer
prone (van Steeg and Kraemer, 1999).
The xeroderma pigmentosum group C
(XPC) gene on chromosome 3 encodes a
940-amino-acid protein that is part of a
heterotrimeric complex with HHR23B
and centrin 2 and acts as damage sensor
and initiator of the nucleotide excision
repair during global genomic repair but
not transcription-coupled repair (Khan
et al., 2006).
We report on an Iraqi family with
two children suffering from XP. Both
parents are consanguine (cousins)
(Figure 1a). The older son, 10 years
old, XP6GO, was born in 1995. He has
photophobia and skin sun-sensitivity.
Hyperpigmentation of sun-exposed skin
began at 6 months of age. One squa-
mous and two basal cell carcinomas
have been excised (Figure 1b). His
6-year-old sister, XP5GO, was born in
1999 and shows very similar symptoms.
At the age of 4 years, she developed a
squamous cell carcinoma. Both patients
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Figure 1. Pedigree, clinical picture, reduced post-UV cell survival, and complementation group assignment of XP5GO and XP6GO. (a) Pedigree of the Iraqi
family. (b) Detailed view of the face of 10-year-old XP patient, XP6GO. Hyper- as well as hypopigmentation and dry skin is visible. The skin shows evidence of
severe premature photodamage. Cheilitis of both lips indicates severe sun damage. Arrow: basal cell carcinoma. (c) Reduced cell survival of XP5GO and
XP6GO fibroblasts compared to normal control fibroblasts (obtained from a skin biopsy from a healthy boy; not exactly age-matched) after irradiation with an
increasing UVC dose. UVC source: CL-100 (LTF Labortechnik, Wasserburg, Germany). Error bars: mean7SD (n¼ 2). (d) Reduced luciferase expression in
XP5GO and XP6GO fibroblasts that is complemented by XPC cDNA in a host cell reactivation (HCR) assay. The HCR assay measures the ability of the host
cells to repair UV-damaged plasmid DNA by assessing the recovery of a reporter gene expression, measured indirectly as enzyme activity of the luciferase
reporter gene. The amount of luciferase expression represents the cellular repair capacity for UV-induced DNA photoproducts. Relative luciferase
activities (percentage of 1,000 J/m2 UVC-irradiated vs unirradiated pCMVLuc plasmid) are depicted (mean7SD; n¼ 3). UVC source: CL-1000
(LTF Labortechnik, Germany).
Abbreviation: XPC, xeroderma pigmentosum group C
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have dry skin, but otherwise exhibit
normal physical and mental develop-
ment without signs of neurologic XP
features like hyporeflexia or deafness
(Emmert et al., 2002). Thus, the clinical
phenotypes of both siblings were the
same with XP5GO showing milder skin
changes owing to her younger age. The
family lives in Germany. They protect
the children from UV exposure via
tightly woven clothing, UV-blocking
sunglasses, cutaneous sun blockers,
and sun-blocking film on the windows.
Participants gave their written informed
consent. The University of Goettingen
approved all described studies. All
clinical studies were conducted accord-
ing to the Declaration of Helsinki
Principles.
To verify an increased cellular UV-
hypersensitivity, we measured cell sur-
vival after UVC irradiation (Slor et al.,
2000). Both fibroblast strains XP5GO
and XP6GO that were established from
skin biopsies revealed a markedly
reduced cell survival with an increasing
UVC dose compared to normal primary
fibroblasts (Figure 1c). XP5GO and
XP6GO fibroblasts showed a reduced
nucleotide excision DNA repair cap-
ability (Figure 1d). In order to assign the
XP5GO and XP6GO fibroblasts to a
specific XP complementation group,
co-transfection was performed with
wild-type containing XP cDNA-con-
taining plasmids (XPA-XPG) along with
the reporter gene plasmid (Emmert
et al., 2002). The co-transfection of
the XPC cDNA-containing plasmid ex-
clusively resulted in enhanced reporter
gene activities, indicating that XPC
cDNA could complement the cellular
DNA repair defect (Figure 1d). This
clearly assigned both strains to the XP
complementation group C.
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Figure 2. XPC mRNA expression analysis, XPC protein expression analysis, and XPC sequence analysis. (a) Reduced XPC mRNA expression in XP5GO and
XP6GO cells was measured using real-time quantitative reverse transcriptase-PCR and SYBR Green (DNA intercalating agent) employing exon 12 spanning
primers as described (Khan et al., 2002). (b) XPC protein levels in fibroblasts from a normal control (AG13145; lane 1), a known XPC patient (XP16VI; lane 2),
the Iraqi girl (XP5GO; lane 3), and the Iraqi boy (XP6GO; lane 4) as assessed by Western blotting. The b-actin protein expression was measured as an internal
control. Relative band intensities (percentage XPC vs actin) are depicted. (c) Sequence analysis of the XPC gene revealing a homozygous insertion/deletion
mutation within XPC exon 9 in XP5GO and XP6GO genomic DNA (Genbank database accession number AF261899). Twelve bases are deleted from the
wild-type sequence and replaced by 25 new bases. Homologies between the inserted bases and the reverse wild-type sequence are indicated.
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In XP-C patients who carry XPC
mutations in both alleles, XPC mRNA
expression is roughly reduced down to
one-third of the normal XPC mRNA
expression mainly owing to nonsense-
mediated message decay (Khan et al.,
2006). As expected, we detectedB33%
XPC mRNA expression in both patient
cell lines compared to normal cells
(Figure 2a). We also measured the XPC
protein expression in XP5GO and
XP6GO cells using Western blot analy-
sis with XPC-specific monoclonal and
anti-b-actin polyclonal antibodies (Khan
et al., 2006). Normal cells showed XPC
protein expression, whereas hardly any
XPC protein expression was detectable
in the patients’ fibroblasts (Figure 2b).
We sequenced the XPC gene in both
patients and their parents using the
primers and conditions as described
(Khan et al., 2002). Sequencing analysis
revealed a novel homozygous complex
insertion/deletion mutation within exon
9 of the XPC gene in both patients
(Figure 2c). A restriction fragment
length polymorphism assay for muta-
tion detection was established using
primer pair S43 and S44 (Khan et al.,
2002) as the mutation creates a new
Msl1 restriction site (data not shown).
Restriction fragment length polymorph-
ism analysis and direct DNA sequen-
cing confirmed that both parents were
heterozygous for the same mutation,
thereby excluding hemizygocity of the
patients. The mutation consists of a
deletion of 12 bp (2,028–2,039) and an
insertion of 25 new base pairs instead
(Figure 2c). This is a very unusual
mutation as all of the XPC mutations
previously reported are base changes,
small deletions or insertions, or splice
site mutations (Chavanne et al., 2000;
Khan et al., 2006). The poly-AT poly-
morphism within XPC intron 9 is also
an insertion/deletion alteration (Khan
et al., 2000). In other XP genes like
XPD, similar causative deletion/inser-
tion mutations have been identified, but
the generation mechanism remained
unclear (Broughton et al., 2001). Inter-
estingly, in our XPC patients, the
inserted sequence contains the inverted
complementary sequence that is de-
leted. In addition, 17 of the 25 bases in
the insertion are 100% identical to a
portion of the human X-chromosome
Xq25–26.2. This might be a part of the
insertion, which may have developed
via homologous recombination. This
mutation leads to a frameshift at codon
641 in the XPC gene (641fs-661ter),
which resulted in reduced XPC mRNA,
greatly reduced expression of XPC
protein, and the clinical phenotype of
xeroderma pigmentosum, including
a greatly increased susceptibility to
sunlight-induced skin cancer.
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